Modulation of RNA splicing as a potential treatment for cancer

Bioengineered Bugs

Volumn 2, Issue 3, 2011, Pages 125-128

  Bauman, John A ^a   Kole, Ryszard ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b AVI BIOPHARMA INC   (United States)

Author keywords

Antisense; Apoptosis; Cancer; Oligonucleotide; Splicing

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PROTEIN BCL X; PROTEIN BCL XL; SOLID LIPID NANOPARTICLE; SPLICE SWITCHING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL PROLIFERATION; CHEMOSENSITIZATION; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; NONHUMAN; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES; RNA SPLICING; RNA, MESSENGER;

EID: 79960282729     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bbug.2.3.15165     Document Type: Article

References (28)

1. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456:470-6.
2. Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 2005; 579:1900-3.
3. Svasti S, Suwanmanee T, Fucharoen S, Moulton HM, Nelson MH, Maeda N, et al. RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice. Proc Natl Acad Sci USA 2009; 106:1205-10.
4. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010; 24:1634-44.
5. Graziewicz MA, Tarrant TK, Buckley B, Roberts J, Fulton L, Hansen H, et al. An endogenous TNFalpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther 2008; 16:1316-22.
6. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A singleblind, placebo-controlled, dose-escalation, proof-ofconcept study. Lancet Neurol 2009; 8:918-28.
7. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357:2677-86.
8. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270:1628-44.
9. Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 2002; 20:1228-33.
10. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5:876-85.
11. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315:856-9.
12. Uren RT, Dewson G, Chen L, Coyne SC, Huang DC, Adams JM, et al. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol 2007; 177:277-87.
13. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60:6101-10.
14. Bauman JA, Li SD, Yang A, Huang L, Kole R. Antitumor activity of splice-switching oligonucleotides. Nucleic Acids Res 2010; 38:8348-56.
15. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
16. Karl E, Zhang Z, Dong Z, Neiva KG, Soengas MS, Koch AE, et al. Unidirectional crosstalk between Bclx L and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ 2007; 14:1657-66.
17. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463:899-905.
18. Mercatante DR, Bortner CD, Cidlowski JA, Kole R. Modification of alternative splicing of Bcl-x premRNA in prostate and breast cancer cells. analysis of apoptosis and cell death. J Biol Chem 2001; 276:16411-7.
19. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277:49374-82.
20. Minn AJ, Boise LH, Thompson CB. Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J Biol Chem 1996; 271:6306-12.
21. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 1999; 17:1097-100.
22. Bauman J, Jearawiriyapaisarn N, Kole R. Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 2009; 19:1-13.
23. Li SD, Chen YC, Hackett MJ, Huang L. Tumortargeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2008; 16:163-9.
24. Li SD, Chono S, Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surfacemodified nanoparticles. J Control Release 2008; 126:77-84.
25. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 2008; 16:942-6.
26. Mercatante DR, Kole R. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: Effects on gene expression. Biochim Biophys Acta 2002; 1587:126-32.
27. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005; 19:1-13.
28. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev 2010; 24:2343-64.